Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM36ONA)

Drug Name
Turofexorate isopropyl Drug Info
Synonyms
629664-81-9; Turofexorate isopropyl; WAY-362450; XL335; isopropyl 3-(3,4-difluorobenzoyl)-1,1-dimethyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate; FXR-450; Turofexorate Isopropyl (XL335); UNII-S6KDM312I5; WAY 362450; S6KDM312I5; WAY362450; XL-335; 3-(3,4-difluorobenzoyl)-1,2,3,6-tetrahydro-1,1-dimethyl-Azepino[4,5-b]indole-5-carboxylic acid 1-methylethyl ester; 1-methylethyl 3-[(3,4-difluorophenyl)carbonyl]-1,1-dimethyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate; FXR 450; Turofexorate isopropyl [USAN:I
Cross-matching ID
PubChem CID
10026128
ChEBI ID
CHEMBL454138
CAS Number
CAS 629664-81-9
TTD Drug ID
D01SYU
VARIDT Drug ID
DR00782

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Parkinson disease 2.04 0.00e+0 176/249 (70.68%) GNAS;DUSP1;PRKACA;...
Renin-angiotensin system 1.95 5.79e-3 20/23 (86.96%) ANPEP;AGTR1;ACE2;...
Circadian entrainment 1.92 3.86e-3 85/97 (87.63%) GNAS;PER3;GNB1;...
Gap junction 1.90 2.89e-3 72/88 (81.82%) GNAS;PRKACA;SRC;...
Oocyte meiosis 1.90 2.32e-3 90/129 (69.77%) PTTG1;PPP3CB;SMC1A;...
Proteasome 1.85 7.72e-3 44/46 (95.65%) PSMB8;PSMB9;PSMA4;...
Retrograde endocannabinoid signaling 1.81 1.32e-2 118/148 (79.73%) GNB1;PRKACA;MAPK13;...
Huntington disease 1.77 1.88e-2 233/306 (76.14%) HDAC2;NDUFB6;PSMA4;...
Endocrine and other factor-regulated calcium reabsorpti... 1.77 2.06e-2 49/53 (92.45%) GNAS;PRKACA;ATP1B3;...
Cardiac muscle contraction 1.77 1.85e-2 64/87 (73.56%) MYL2;TNNC1;TPM3;...
GnRH signaling pathway 1.76 1.79e-2 80/93 (86.02%) GNAS;MAP3K1;PRKACA;...
Long-term depression 1.76 1.64e-2 55/60 (91.67%) GNAS;IGF1;GUCY1B1;...
DNA replication 1.75 1.69e-2 34/36 (94.44%) PCNA;RFC2;POLE3;...
Dopaminergic synapse 1.74 1.98e-2 115/132 (87.12%) GNAS;PPP3CB;GNB1;...
Cholesterol metabolism 1.74 1.85e-2 44/50 (88%) APOE;APOB;APOA2;...
Oxytocin signaling pathway 1.72 2.03e-2 128/154 (83.12%) GNAS;PPP3CB;PRKACA;...
Thermogenesis 1.72 1.98e-2 173/232 (74.57%) GNAS;ACSL5;PRKACA;...
Oxidative phosphorylation 1.68 2.70e-2 93/133 (69.92%) NDUFB6;NDUFAB1;ATP5MG;...
Progesterone-mediated oocyte maturation 1.64 4.02e-2 75/100 (75%) CCNB1;MAD2L1;IGF1;...
Amyotrophic lateral sclerosis 1.64 3.88e-2 267/364 (73.35%) PPP3CB;DAXX;NEFH;...
Dilated cardiomyopathy 1.61 4.63e-2 86/96 (89.58%) GNAS;TTN;IGF1;...
Rheumatoid arthritis -1.80 4.59e-2 78/93 (83.87%) ATP6V1C1;IL11;ATP6V1B1;...
ECM-receptor interaction -1.88 3.01e-2 80/88 (90.91%) LAMB2;ITGA3;LAMA5;...
Staphylococcus aureus infection -1.92 4.30e-2 72/95 (75.79%) C2;HLA-DPB1;C1QB;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 2H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HL-60 CVCL_0002 Homo sapiens 0.08uM - 10uM 2H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H